Is LLY a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

7,094 people get LLY articles and Market Currents by email alert.

Get email alerts on LLY »

FOCUS | PRO | RELATED | TRANSCRIPTS | NEWS & PR

Eli Lilly: Cymbalta Antidepressant Sales Forecast
Pharma Reports • Wed, Jun 19
Eli Lilly's Alzheimer's Beta-Secretase Inhibitor Hits The Skids
Derek Lowe • Fri, Jun 14 • 2 Comments
Diabetes And Oncology Might Cushion Eli Lilly's Fall Off A Patent Cliff
Cory Renauer • Fri, May 24 • 1 Comment
Eli Lilly's Promising Stage III Pipeline Could Jumpstart Its Dividend
Valuentum • Fri, Apr 26
Whisper Number Impact: Earnings Preview For Eli Lilly
WhisperNumber • Tue, Apr 23
Eli Lilly's Big Bet On Diabetes
Peter Geschek • Tue, Apr 23 • 1 Comment
Clean Superiority Sweep For Dulaglutide Could Reshape Diabetes Market
EP Vantage • Wed, Apr 17 • 1 Comment
Reasons To Consider Eli Lilly Over Other Pharmaceutical Giants
Robinson Roacho • Fri, Mar 22 • 4 Comments
Eli Lilly: A Bull Run Corroborated By Its Fundamentals
StockRiters • Wed, Mar 6 • 3 Comments
2013, A Year Of Turmoil For Eli Lilly
Bio Matt • Sat, Feb 16 • 4 Comments
Eli Lilly May Have The Best Chance At Keeping The Momentum Going
Stephen Simpson • Wed, Jan 30 • 1 Comment
Pfizer And Eli Lilly Sit At New Highs; Which Is The Better Buy?
Teresa Dawn • Wed, Jan 30 • 6 Comments
Eli Lilly: Buy, Sell Or Hold
Pharma Reports • Wed, Jan 9 • 5 Comments
Eli Lilly's Strong Outlook Is Comforting Amidst $6 Billion In Patent Expirations
The Value Investor • Sun, Jan 6 • 4 Comments
Eli Lilly's Brave Alzheimer's Talk
Derek Lowe • Wed, Dec 12, 2012 • 3 Comments
Why Eli Lilly Is Worth Every Penny
Valuentum • Tue, Dec 11, 2012 • 2 Comments
Pfizer's Xeljanz Gets Approval, While Lilly's Baricitinib Looks Strong
Kevin CC • Wed, Nov 21, 2012 • 8 Comments
Lilly: The Worst Play In Big Pharma?
Cris Frangold • Thu, Nov 15, 2012 • 6 Comments
Eli Lilly: Cymbalta Patent Cliff
Pharma Reports • Thu, Nov 1, 2012
Is Eli Lilly Still A Solid Dividend Investment For The Long Run?
Doug Carey • Wed, Oct 31, 2012 • 1 Comment

To learn more about Seeking Alpha Pro, click here.

The Neuralstem You Don't Know
Jason Napodano • Wed, Jun 19 • 4 Comments
CryoPort's Game-Changer In Frozen Biological Shipping
Brian Marckx • Tue, Jun 18 • 2 Comments
Biodel Primed To Capitalize On Next Generation Treatments In The $10B Diabetes Market
StockMatusow • Tue, Jun 18 • 33 Comments
Successor To Humira? AbbVie And Galapagos Work On It
Peter Geschek • Mon, Jun 17 • 1 Comment
Good News For This Small-Cap Biotech: Eli Lilly Wants To Develop Its Diabetes Drug
PropThink • Mon, Jun 17 • 7 Comments
Alkermes Changing The Standard Of Care For Schizophrenia
Jason Napodano • Thu, Jun 13 • 3 Comments
When It Comes To Biotech, Diversity Is Key
Mike Perinotti • Wed, Jun 12 • 5 Comments
Warning: The Rebound May Be Over For Big Pharma
StreetAuthority • Tue, Jun 11
Interest Rates Up Round 1 - Sorting Through The Data
Daniel R Moore • Fri, Jun 7 • 5 Comments
Bristol-Myers Squibb: The Untold Story Of Led Zeppelin
Pharma Reports • Thu, Jun 6 • 13 Comments
2 Under-Covered Pharma Stocks With Yields Above 3%
Labutes IR • Tue, Jun 4
Celgene Stock Still Has Plenty Of Room To Grow Due To A Strong Product Line
A John Hodge • Tue, Jun 4 • 1 Comment
Anacor Pharmaceuticals: A Small Cap With Tremendous Upside And Multiple Short To Mid Term Catalysts
Alexander Maxwell • Tue, Jun 4 • 1 Comment
The Long Case For United Therapeutics
Todd Campbell • Tue, Jun 4
The Dope On A Forest Labs Takeover
YCharts • Tue, Jun 4 • 1 Comment
Johnson & Johnson - Avoid This Safety Stock
The Ethical Investor • Sun, Jun 2 • 31 Comments
Billionaire Jim Simons' Top Dividend Stock Holdings
Insider Monkey • Fri, May 24 • 3 Comments
6 Ways You Can Profit From Molecular Diagnostics
Cory Renauer • Wed, May 22 • 15 Comments
Pricing A Highly Probable Takeover Of MannKind
George Rho • Wed, May 22 • 108 Comments
What Will $2 Million Get You In Retirement?
Doug Carey • Thu, May 16 • 146 Comments

Eli Lilly's CEO Presents at Goldman Sachs Healthcare Conference (Transcript)
Wed, Jun 12 • 1 Comment
Eli Lilly's CEO Discusses Q1 2013 Results - Earnings Call Transcript
Wed, Apr 24
Eli Lilly Management Presents at 2013 Barclays Global Healthcare Conference (Transcript)
Tue, Mar 12
Eli Lilly's Management Discusses Q4 2012 Results - Earnings Call Transcript
Tue, Jan 29
Eli Lilly & Company's CEO Hosts 2013 Financial Guidance Conference (Transcript)
Fri, Jan 4
Eli Lilly & Co. Management Discusses Q3 2012 Results - Earnings Call Transcript
Wed, Oct 24, 2012
Eli Lilly & Co. Management Discusses Q2 2012 Results - Earnings Call Transcript
Wed, Jul 25, 2012 • 1 Comment
Eli Lilly's Management Host Lilly Diabetes Pipeline Update Call (Transcript)
Tue, Jun 12, 2012
Eli Lilly & Co.'s CEO Discusses Q1 2012 Results - Earnings Call Transcript
Wed, Apr 25, 2012
Eli Lilly Management Host Ixekizumab Phase II Psoriasis Data Conference Call (Transcript)
Tue, Apr 10, 2012
Eli Lilly & Co.'s CEO Discusses Q4 2011 Results - Earnings Call Transcript
Tue, Jan 31, 2012 • 1 Comment
Eli Lilly's CEO Presents at The 30th Annual JPMorgan Chase Healthcare Conference (Transcript)
Wed, Jan 11, 2012
Eli Lilly & Co.'s CEO Discusses Q3 2011 Results - Earnings Call Transcript
Thu, Oct 20, 2011 • 1 Comment
Eli Lilly & Co. Management Discusses Q2 2011 Results - Earnings Call Transcript
Thu, Jul 21, 2011
Eli Lilly & Co. Management Discusses Q1 2011 Results - Earnings Call Transcript
Mon, Apr 18, 2011 • 1 Comment
Eli Lilly & Co.'s CEO Discusses Q4 2010 Results - Earnings Call Transcript
Thu, Jan 27, 2011
Eli Lilly & Co. CEO Discusses Q3 2010 Results - Earnings Call Transcript
Thu, Oct 21, 2010
Eli Lilly & Co. Q2 2010 Earnings Call Transcript
Thu, Jul 22, 2010
Eli Lilly and Company Q1 2010 Earnings Call Transcript
Mon, Apr 19, 2010 • 1 Comment
Eli Lilly and Co. Q4 2009 Earnings Call Transcript
Thu, Jan 28, 2010 • 1 Comment

Lilly Issues Alert for Illegal Scams Involving Fraudulent Checks and Online Job Requests

PR Newswire (Wed, 3:15PM)
FDA Probes 2 Deaths Possibly Related to Lilly Drug

at Fox Business (Tue, 12:35PM)
Lilly Declares Third-Quarter 2013 Dividend

PR Newswire (Tue, 10:30AM)
New Data Showed LIVALO® (pitavastatin) 4 mg had Neutral Effects on Fasting Serum Glucose and HbA1c Levels in HIV-infected Adults with Dyslipidemia

PR Newswire (Mon, 11:30AM)
Lilly Diabetes, Kris Freeman Kick off Summer with 9th Annual Diabetes Summer Camp Tour

PR Newswire (Mon, 8:00AM)
Lilly Voluntarily Terminates Phase II Study for LY2886721, a Beta Secretase Inhibitor, Being Investigated as a Treatment for Alzheimer's Disease

PR Newswire (Thu, 4:39PM)
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company Statement on the ADA Request for Independent Review of Incretin-Based Therapies

PR Newswire (Thu, 2:34PM)
Lilly and Incyte Announce Baricitinib Efficacy and Safety Data from the Open-Label, Long-Term Extension of the Phase 2b JADA Study in Patients with Rheumatoid Arthritis

PR Newswire (Thu, 6:00AM)
Cloud Computing: CNBC Explains

at CNBC.com (Jun 11, 2013)
Lilly to Highlight Late-Stage Pipeline Molecules at the 73rd American Diabetes Association Scientific Sessions®

PR Newswire (Jun 11, 2013)
Boehringer Ingelheim and Eli Lilly and Company Alliance to Feature 34 Presentations on Type 1 and Type 2 Diabetes at the 73rd American Diabetes Association Scientific Sessions®

PR Newswire (Jun 11, 2013)
PRONOUNCE Study Does Not Achieve Primary Superiority Endpoint for ALIMTA® (pemetrexed for injection), Similar PFS and OS Results Were Observed Between the Two Drug and the Three Drug Regimens in the Treatment of NSCLC

PR Newswire (Jun 3, 2013)
New Mobile App Assists Oncologists In Navigating Ever-Evolving Sea Of Cancer Information

PR Newswire (May 31, 2013)
Lilly Statement on Indiana Biosciences Research Institute

PR Newswire (May 30, 2013)
Lilly to Present at Goldman Sachs Global Healthcare Conference

PR Newswire (May 30, 2013)
New Data on FORTEO® (teriparatide [rDNA origin] injection) Show Increased Bone Mineral Density in Men with Glucocorticoid-Induced Osteoporosis

PR Newswire (May 29, 2013)
From Research Labs to Doctors' Offices, Health Care Providers at Lilly Play Important Role in Bringing New and Innovative Medicines to Patients

PR Newswire (May 20, 2013)
Lilly Oncology to Release New Pipeline Data at ASCO 2013

PR Newswire (May 14, 2013)
Lilly Provides Update on CEO Dr. John Lechleiter

PR Newswire (May 14, 2013)
Lilly To Take $30M Charge After Disappointing Drug Trial

at Fox Business (May 10, 2013)

LLY vs. ETF Alternatives

Company Description

Eli Lilly and Company (the “Company” or “Registrant”) was incorporated in 1901 in Indiana to succeed to the drug manufacturing business founded in Indianapolis, Indiana, in 1876 by Colonel Eli Lilly. We discover, develop, manufacture, and sell products in one significant business... More

Sector: Healthcare

Industry: Drug Manufacturers - Major

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Wednesday, June 19, 5:34 AM The FDA is investigating the injectable form of Eli Lilly's (LLY) antipsychotic drug Zyprexa - which generated $1.7B in sales last year - after two patients died within four days of receiving the treatment. The patients had very high levels of the drug in their system, which can cause delirium, cardiac arrest and arrhythmias and coma or loss of consciousness. However, the agency isn't yet saying they received an overdose or an inappropriate amount. 2 Comments [Healthcare]
Tuesday, June 18, 11:23 AM Eli Lilly and Company (LLY) declares $0.49/share quarterly dividend, in line with previous. Forward yield 3.78%. For shareholders of record August 15. Payable September 10. Ex-div date August 13. (PR) Comment! [Dividends]
Monday, June 17, 9:40 AM Eli Lilly (LLY +1.3%) agrees to take over the development of Type 2 diabetes treatment TT-401 from Canadian firm Transition Therapeutics (TTHI +4.8%). Lilly will pay $7M upfront to Transition and $240M in milestone payments as well as royalties, although Transition will pay Lilly $14M in three installments during a mid-stage study. (PR) 1 Comment [Healthcare]
Monday, June 17, 8:54 AM BofA cuts its recommendation on Novo Nordisk (NVO -2.35%) to "neutral" from "buy" on concerns that data that Eli Lilly (LLY) is due to present at a conference later this week will show that the latter's dulaglutide diabetes treatment is better than Novo's Victoza. Novo investors are also worried about Sanofi's (SNY +2.4%) Lantus and a combination of the product with another drug called Lyxumia. Sanofi is scheduled to present at the conference as well but Novo is not. Comment! [Healthcare]
Thursday, June 13, 6:44 PM Eli Lilly (LLY) terminates mid-stage clinical trials of LY2886721, an experimental Alzheimer's disease drug designed to inhibit beta secretase, after four patients had abnormal liver biochemical tests. Beta secretase contributes to the buildup of amyloid plaque in the brain that is believed to cause Alzheimer's, and the halt is another setback for the drug giant in the hunt for a new therapy that can halt or reverse the progression of the neuro-degenerative disease. Shares -0.5% AH. Comment! [Healthcare]
Thursday, June 13, 8:08 AM Eli Lilly (LLY) and Incyte (INCY) say clinical benefits observed after 24-weeks in rheumatoid arthritis patients taking baricitinib are sustained through 52-weeks. Safety results are "consistent" with results from the shorter study, although there were some adverse events. The safety profile is "acceptable and [the] side effects have generally been straightforward to manage," a steering committee member says. Separately, INCY says the FDA has updated prescribing information on Jakafi. (Previously: Morgan Stanley talks Jakafi side effects) Comment! [Healthcare]
Monday, June 3, 2:05 PM Eli Lilly (LLY -0.4%) says its Alimta drug in combination with carboplatin didn't meet the primary superiority endpoint in a Phase III study of patients with nonsquamous non-small cell lung cancer. The trial compared the combination to a regimen of paclitaxel, carboplatin and bevacizumab, but found there wasn't a significant difference between the treatment arms for secondary study goals of progression-free survival, overall survival, overall response rate and disease control rate. Comment! [Healthcare]
Sunday, June 2, 3:24 AM Merck KGaA's (MKGAF.PK) Erbitux treatment helped patients with metastatic colon cancer live around four months longer than Roche's Avastin in a head-to-head study. However, the overall response rate, as measured by tumor shrinkage, was the about same, as was the amount of time it took for the disease to worsen. A larger trial of the drugs is due to take place next year. Merck's U.S. partners in Erbitux are Eli Lilly (LLY) and Bristol-Myers Squibb (BMY). The findings were presented at the annual meeting of American Society of Clinical Oncology. Comment! [Healthcare]
Tuesday, May 28, 8:10 AM Add Eli Lilly (LLY) to Jefferies' big pharma upgrades, as the company is raised to Hold from Underperform (price target to $49 from $44) on a lack of near term downside risks and a healthy dividend. Nevertheless, expect FY14 EPS to come in 5-10% below consensus, analyst Jeff Holford says. Meanwhile, Merck (MRK), Abbott (ABT), and Novartis (NVS) are all top "restructuring plays." Jefferies says "the probability of significant spin-outs" for MRK should increase in 2014 and puts a sum-of-the-parts valuation of $54.30 on the stock. Comment! [Healthcare]
Friday, May 10, 9:07 AM Eli Lilly (LLY) slips 1% premarket after saying a study of enzastaurin "did not show a statistically significant increase compared to placebo in disease-free survival" for patients with diffuse large B-cell lymphoma. LLY will discontinue development and take a $30M Q2 R&D expense. FY13 guidance unchanged. (PR) 2 Comments [Healthcare]
Tuesday, May 7, 6:20 AM Eli Lilly (LLY) declares $0.49/share quarterly dividend, in line with previous. Forward yield 3.60%. For shareholders of record May 16. Payable June 10. Ex-div date May 14. (PR) Comment! [Dividends]
Monday, May 6, 1:36 PM Merck (MRK -1.3%) gets no love today from the FDA's approval of Liptruxet late Friday, as the stock is likely dragged down with the rest of the big pharma names on the back of a CNBC report that criticizes their earnings so far. The article points to the fact that pharmaceutical companies have seen a 4.7% contraction in earnings, and a 3.2% drop in revenue this quarter. Why? Morningstar's Damien Cover says there are two primary reasons: FX impact, especially from the yen, and intensified generic competition from patent losses. Comment! [Healthcare, On the Move]
Wednesday, April 24, 3:28 PM In what seems to be a trend in companies reporting today, Eli Lilly (LLY -3.6%) dips after posting a mixed Q1, beating on a per share basis but coming up short on revenue. Net earnings rose 53% Y/Y, primarily from a gain from selling rights to a diabetes drug, but a slowdown in its Elanco animal-health kept overall revenue flat. LLY has been cultivating sales growth in its animal-health division as a strategy for getting through the wave of patent expirations, but sales in the unit rose only 2% for the quarter, compared to 21% growth during the same prior-year period. Comment! [Healthcare, Earnings, On the Move]
Wednesday, April 24, 6:31 AM Eli Lilly (LLY): Q1 EPS of $1.14 beats by $0.08. Revenue of $5.60B (flat% Y/Y) misses by $0.06B. (PR) 1 Comment [Earnings, Breaking News, Healthcare]
Wednesday, April 24, 12:05 AM Notable earnings before Wednesday’s open: ABB, ABX, ASH, ATI, AVY, BA, BYD, CFR, CKSW, COR, CP, CS, CVE, DPS, EDU, ELN, EMN, ERIC, F, FDML, GD, GLW, GRA, HCBK, HES, ICON, LAD, LL, LLY, LO, MDCO, MSI, MTH, NDAQ, NOC, NS, NVS, NYCB, OC, OCR, OSIS, PG, PLD, PX, RES, ROK, S, SO, SVU, TEL, TKR, TMO, TROW, TUP, USG, VLY, VMED, WAB, WHR, WLP, WM, WYN Comment! [Earnings]
Tuesday, April 23, 5:30 PM Notable earnings before Wednesday’s open: ABB, ABX, ASH, ATI, AVY, BA, BYD, CFR, CKSW, COR, CP, CS, CVE, DPS, EDU, ELN, EMN, ERIC, F, FDML, GD, GLW, GRA, HCBK, HES, ICON, LAD, LL, LLY, LO, MDCO, MSI, MTH, NDAQ, NOC, NS, NVS, NYCB, OC, OCR, OSIS, PG, PLD, PX, RES, ROK, S, SO, SVU, TEL, TKR, TMO, TROW, TUP, USG, VLY, VMED, WAB, WHR, WLP, WM, WYN Comment! [Earnings]

Ypa Finance
$LLY is a part of our bias-free quantitative S&P500 Dividend Portfolio http://bit.ly/15ZIU78
Thu, 10:52 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Nathaniel Matherson
New Post "Profiting From Diabetes Expenses" on Circa Alpha: http://bit.ly/1b8V5zm $MDT $LLY
Jun 6, 10:55 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Optionstrader7
$LLY Nice bounce off 100dma and recaptured 50dma. Goes ex tomorrow. LONG
May 13, 12:07 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

The Wall Street Transcript
Incyte Corporation ($INCY) and Eli Lilly ($LLY) Eye $20 Billion Market Opportunity with Rheumatoid Arthritis Drug- http://su.pr/ARL5Dl
Apr 30, 12:52 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ltfinger
Returning Downgrades (4/25/13): $AHL, $BLL, $BMY, $CAP, $CRAI, $CRR, $CRS, $HRC, $INTU, $LLY, $MLNX, $MMM, $NSH, $QCOM, $SEIC, $SWK, $SWY
Apr 26, 11:05 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

jelrod3
$LLY usually declares div around mid-April. They are 10 days late. Hmmm...
Apr 25, 5:14 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Nathaniel Matherson
Buy This Stock On Relative Weakness: $MRK $LLY $GSK http://bit.ly/YRKc3U
Apr 16, 7:46 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Dividend Sheet
$ARR $PBI and $GEO are tomorrow's best yielding ex-dividend stocks - http://stks.co/aKgZ - I like $LLY $DD $CVX and $WAG
Feb 12, 4:54 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Tradevestor
$MRK $LLY $PFE Extra tax or not, another divdend increase on its way ?http://seekingalpha.com/a/lke1
11/14/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Paul Zimbardo
Ex-Dividend Opportunities http://seekingalpha.com/a/lew9 ALE ARR DUK EXC HE LLY PBI SJR #Stocks #Dividends #News #Investing #Utilities
11/13/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

Henry Swann
Goldman Sachs upgrades LLY-Eli Lilly, from a Sell to Neutral - Now how can you take them seriously? The stock is way up - what a waste.
10/9/12
Reply (6)

• !Report Abuse
View all 6 replies
Youngone91: i can only remember one goldman call being correct and that was to close crude/platinum positions in april 2011
10/15/12
• !Report Abuse
Pharma Reports: What about Cymbalta patent cliff: http://is.gd/LLYcymbalta Just on the heel of Zyprexa patent expiry
11/1/12
• !Report Abuse
Add a reply...

140 characters

Randy Lacen
Pharma Stocks to choose from: QCOR, SPPI, LLY, CAH, ABT, CBST, AKRX, VRTX, ANIK, USNA, CTRX
6/27/12
Reply (1)

• !Report Abuse
View all 1 replies
vireoman: Okee-doke
6/27/12
• !Report Abuse
Add a reply...

140 characters

Dividend Sheet
Five S&P 500 High Yield Stocks With Double Digit Earnings Growth + http://bit.ly/zwFuTI + $WIN $HCN $VZ $PBCT $LLY
2/25/12
Reply (3)

• !Report Abuse
View all 3 replies
Dividend Sheet: +14.42 percent for next year and -8.18 percent for the next five years
2/26/12
• !Report Abuse
Ocean Man: $3.18 for 2012 and $4.41 for 2011.
2/26/12
• !Report Abuse
Add a reply...

140 characters

Windsun33
And I see I missed out badly not selling my LLY and buying RAIL
2/17/12
Reply (3)

• !Report Abuse
View all 3 replies
nasalpancho: take out the word solar and you can ask that question every day lol
2/17/12
• !Report Abuse
Windsun33: FSTR is so thinly traded and volatile I have not really considered it. Other rail sector not doind that good today
2/17/12
• !Report Abuse
Add a reply...

140 characters

Ocean Man
Look at a 1-year chart for LLY. 34 to 42 - impressive, that's a 24% gain. That handily beats the market which was flat, and it's sector.
1/27/12
Reply (4)

• !Report Abuse
View all 4 replies
brownlee30: I second this. Been looking at adding a short position on it..
1/27/12
• !Report Abuse
mitrado: I don't short stocks... but you're right. I wouldn't buy LLY at these levels.
2/5/12
• !Report Abuse
Add a reply...

140 characters

briandiplacido
Watching LLY since Ocean's post 1/27, today read they are freezing some salaries, interesting.
2/3/12
Reply (9)

• !Report Abuse
View all 9 replies
tashe: That seems to be the plan
2/3/12
• !Report Abuse
Ocean Man: I'll likely wait 10 days to short that, don't want to be on the wrong side of any dividend run-up.
2/3/12
• !Report Abuse
Add a reply...

140 characters

Larry Smith
MAT, LLY, PFE, UPS all beat forecasts
1/31/12
Reply (2)

• !Report Abuse
View all 2 replies
mun2000: rally today big time
1/31/12
• !Report Abuse
Larry Smith: Should add ADM was a BIG miss.
1/31/12
• !Report Abuse
Add a reply...

140 characters

Ocean Man
Extremely happy w/ this week. Made $11,000 on GLD straddle w/ calls up 140%, TIF calls up 58%, LLY puts up 44%, MCD calls up 13%, AKS calls
1/27/12
Reply (8)

• !Report Abuse
View all 8 replies
Ocean Man: Thanks, guys. Working on a few ideas for next week. CLCT is current play, and I like DPS and CRZO for full-year plays.
1/28/12
• !Report Abuse
briandiplacido: CRZO my #1 horse for 2012 so far. Hope to see $30+before summer.
1/30/12
• !Report Abuse
Add a reply...

140 characters

C Meyer
Bot T 29.40 yesterday to yld 6%. LLY & AEP on today's radar.
1/27/12
Reply (1)

• !Report Abuse
View all 1 replies
Ocean Man: I'm thinking about T too. I'm about to write a Stocktalk about LLY, come join.
1/27/12
• !Report Abuse
Add a reply...

140 characters

Ocean Man
I don't know what you TA guys call it, but the LLY chart is doing that thing where it's about to go down. Bought Feb 41 puts.
1/18/12
Reply (1)

• !Report Abuse
View all 1 replies
Ocean Man: Practically free since a 50-cent dividend will be coming out of the price between now and expiration....
1/18/12
• !Report Abuse
Add a reply...

140 characters

Ryan Mallory
Short Setup on Eli Lilly LLY http://bit.ly/wCT3HH
1/13/12
Reply (2)

• !Report Abuse
View all 2 replies
Ricardo Espinosa: Looks good, thanks for the link.
1/13/12
• !Report Abuse
Ryan Mallory: No problem, Richard - glad I could help.
1/16/12
• !Report Abuse
Add a reply...

140 characters

Youngone91
sell or hold LLY?
12/15/11
Reply (2)

• !Report Abuse
View all 2 replies
Chines33: Hold.
12/15/11
• !Report Abuse
Youngone91: Ok I advised my mom to pick it up around 34, if it was my own acc I wouldn't have questioned but I try to be more conservative with her
12/15/11
• !Report Abuse
Add a reply...

140 characters

cranmer
What's up with LLY today?
12/6/11
Reply (2)

• !Report Abuse
View all 2 replies
mitrado: Speculation, baby, pure speculation! :-D I was hoping to buy some LLY stock... but now, I'll just forget that idea. It's way above my limit.
12/7/11
• !Report Abuse
mitrado: Anyway, I'm not buying anything at all before the possible market crash. Do anyone believe European leaders will come up with a good plan!?
12/7/11
• !Report Abuse
Add a reply...

140 characters

Ocean Man
Who is most likely to beat this week: C, HAL, IBM, WFC, AAPL, BAC, KO, CSX, GS, INTC, JNJ, UNH, ABT, AXP, EBAY, MS, UTX, WYNN, T, LLY, COF,
10/16/11
Reply (7)

• !Report Abuse
View all 7 replies
Hillbilly Stock Star: WYNN.......I am playing hard! Long.
10/16/11
• !Report Abuse
1ras1: i believe ms already pre announced a beat
10/16/11
• !Report Abuse
Add a reply...

140 characters

LLY Eli Lilly and Company

LLY

Eli Lilly and Company